Serum FGF-23 and Vitamin D Deficiency
Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term
2 other identifiers
observational
N/A
1 country
1
Brief Summary
We aimed to determine the effect of vitamin D replacement therapy on serum FGF-23 concentrations in vitamin D deficient women and to compare the FGF-23 concentrations of vitamin D deficient patients with healthy subjects and patients with genetically-determined hypophosphatemic rickets.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 12, 2010
CompletedFirst Posted
Study publicly available on registry
April 13, 2010
CompletedApril 13, 2010
August 1, 2009
April 12, 2010
April 12, 2010
Conditions
Keywords
Study Arms (3)
Vitamin D deficient females
(n =18, mean age 29.1±9.9 yrs)
vitamin D sufficient healthy females
(control group; n = 19, mean age 28.5±5.2 yrs)
genetically-determined hypophosphatemic rahitis
(n=13, mean age 26.5±15.1 yrs)
Eligibility Criteria
Group 1: Eighteen premenopausal female patients with a diagnosis of vitamin D deficient osteomalacia were included in this group. Vitamin D deficiency was diagnosed according to the serum 25 hydroxy vitamin D3 (25OHD) concentrations (\< 30 ng/mL). Reasons for vitamin D deficiency were verified as insufficient exposure to sunlight, frequent parturition and prolonged lactation. All of these patients received a standard treatment regimen; oral Vitamin D3 150 000 IU once for all and subsequently 880 IU D3 and 1000 mg calcium carbonate for six weeks. This group was also evaluated after replacement therapy at sixth week. Group 2: Nineteen healthy premenopausal women who had normal levels of serum 25OHD Vitamin (\>30 ng/mL) composed the control group. Group 3: Thirteen hypophosphatemic rickets (3 autosomal dominant and 10 X-linked; 9 female and 4 male) were included in this group.
You may qualify if:
- Serum 25OHD Vitamin \<30 ng/mL for group 1
- Serum 25OHD Vitamin \>30 ng/mL for control group
You may not qualify if:
- Receiving medication(s) affecting bone metabolism
- History of gastrointestinal disease and malabsorption
- History of renal and liver disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism
Istanbul, 34390, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 12, 2010
First Posted
April 13, 2010
Last Updated
April 13, 2010
Record last verified: 2009-08